Product Theater

Maximize Your Visibility with a Product Theater

Product Theaters are turnkey, 45-minute marketing presentations about your company’s products or services. These sessions do not offer CME credit; rather, they give exhibitors the freedom to create a presentation centered on their company’s products. 

Only DDW industry supporters who have secured a booth are eligible to apply for a slot for a product theater, subject to availability and adherence to all published guidelines.

If you are interested in booking a Product Theater for DDW, please reach out to our account managers below. If you are not currently an industry supporter, you will be required to secure booth space before you will be able to secure a Product Theater..

Companies A-G:
Nia Murphy
Account Manager
Industry Sales and Operations
301-941-9789 | nmurphy@gastro.org

Companies H-Z:
Tessa Ayala
Account Manager
Industry Sales and Operations
301-657-2176 | tayala@gastro.org

Calendar

Friday, May 21, 2021

9:30 a.m.Ferring Pharmaceuticals, Inc.
The Power of the Microbiome-Can it be unlocked to break the cycle of recurrent Clostridioides difficile infection (CDI)
9:30–10:15 a.m.
DDW Theater 1 - Hall B2
This program will discuss the role of the microbiome in overall health and explore the relationship between the gut microbiome and CDI.
10:30 a.m.STERIS Endoscopy
Liquid Nitrogen Cryotherapy in the Endoscopic Management of Barrett’s Esophagus & Esophageal Neoplasia: Updates, Current Controversies and Challenges
10:30 a.m.–11:15 a.m.
DDW Theater 2 - Hall F2
11:30 a.m.AbbVie
UC Powerful Evidence
11:30 a.m.–12:15 p.m.
DDW Theater 1 - Hall B2
12:30 p.m.AbbVie
Advancing Care for Crohn's Disease
12:30–1:15 p.m.
DDW Theater 2 - Hall F2
Speaker: Anita Afzali, MD, MPH, FACG, AGAF, Medical Director, OSU IBD Center, Ohio State Inflammatory Bowel Disease Center, Hilliard, OH.
1:30 p.m.Takeda
From Diagnosis to Treatment: Assessing Moderately to Severely Active Crohn’s Disease
1:30–2:15 p.m.
DDW Theater 1 - Hall B2
Anita Adzali, MD will present an interactive case study discussing a hypothetical Crohn’s disease patient. This presentation will discuss patient presentation, biomarker and endoscopy findings, treatment options, and follow-up.
2:30 p.m.EndoGastric Solutions
TIF 2.0 - Changing the GERD Paradigm
2:30–3:15 p.m.
DDW Theater 1 - Hall B2
The TIF 2.0 procedure using the EsophyX Z+ device is shaping future GERD treatment. During this presentation, innovators will discuss the latest clinical results and how TIF 2.0 can be used in a broader spectrum of patient populations.
Janssen Biotech, Inc.
Optimizing Biologic-Naïve Patient* Outcomes in Crohn’s Disease with STELARA® (ustekinumab) *In adults with moderately to severely active Crohn's disease
2:30–3:15 p.m.
DDW Theater 2 - Hall F2
Please visit Booth 3526 for Product Theater details.
Speakers: Bincy Abraham, MD, MS and Stephen B. Hanauer, MD
3:30 p.m.Gilead Sciences, Inc.
Hepatitis D Virus Infection: Epidemiology, Pathophysiology, and Clinical Management
3:30–4:15 p.m.
DDW Theater 1 - Hall B2
This informative presentation provides clinicians with an in-depth review of hepatitis delta virus (HDV), the most severe form of chronic viral hepatitis. Topics covered will include its global prevalence, relationship with hepatitis B virus, progression to advanced liver disease, and who to screen for HDV.
Bristol Myers Squibb
Another Day is Dawning in the Control of UC: ZEPOSIA (Ozanimod), A Once-Daily Oral Therapy
3:30–4:15 p.m.
DDW Theater 2 - Hall F2
Join us for a program where gastroenterologist Dr. Amar Naik and neurologist Dr. Barry Hendin will provide an overview of the clinical profile of ZEPOSIA, the first and only sphingosine 1-phosphate receptor modulator (S1P) for the treatment of moderately to severely active ulcerative colitis, with first approval in relapsing multiple sclerosis (MS).

Saturday, May 22, 2021

9:30 a.m.Bristol Myers Squibb
Patient Identification and Treatment of Adult Patients with Moderately to Severely Active UC with ZEPOSIA (Ozanimod)
9:30–10:15 a.m.
DDW Theater 1 - Hall B2
Join us for an overview of the efficacy and safety profile of ZEPOSIA and a conversation with Dr. Miguel Regueiro on patient identification and treatment considerations for your patients with moderately to severely active UC.
Speaker: Dr. Miguel Regueiro, MD.
10:30 a.m.AbbVie and Ironwood
A Proactive Way to Treat IBS-D: Post-Marketing Information and Phase 4 Data
10:30–11:15 a.m.
DDW Theater 2 - Hall F2
Please join us in a clinical review of Phase 4 data and the latest post-marketing information on a proactive treatment that may help your IBS-D patients. IBS-D is a chronic functional GI disorder that affects approximately 16 million people.
Speaker: Darren Brenner, MD
11:30 a.m.AbbVie
Could It Be More Than Occasional Constipation? Time to Have a Deeper Conversation with Your Adult Patients with IBS-C
11:30 a.m.–12:15 p.m.
DDW Theater 1 - Hall B2
IBS-C impacts nearly 11.5 million Americans. It’s a chronic condition that is characterized by constipation, and burdensome symptoms like abdominal pain, bloating and discomfort. Research shows many patients are uncomfortable discussing the totality of their symptoms with their healthcare provider. Join this clinical review to learn more about a treatment that may help adults with IBS-C.
12:30 p.m.Phathom Pharmaceuticals
Unmet Needs in the Treatment of Acid-related Disorders
12:30–1:15 p.m.
DDW Theater 2 - Hall F2
Phathom Pharmaceuticals, a biopharmaceutical company focusing on novel treatments for GI disorders, is excited to host Colin Howden, MD, GRCP, emeritus professor at the University of Tennessee, to discuss unmet needs in the treatment of acid-related disorders.
1:30 p.m.Medtronic
Medtronic Innovation Updates for Bleeding Management
1:30–2:15 p.m.
DDW Theater 1 - Hall B2
This presentation will highlight a new topical powder for endoscopic hemostasis, Nexpowder™. Learn more about this new technology and hear from experts about their clinical experience in managing active bleeding and preventing delayed bleeding in nonvariceal upper GI bleeding. Join us to gain insights into what’s next in nonvariceal UGIB management.
2:30 p.m.Regeneron and Sanofi Genzyme
Eosinophilic Esophagitis: A Clinical Perspective of Type 2 Inflammation
2:30–3:15 p.m.
DDW Theater 1 - Hall B2
EoE is a progressive, local manifestation of underlying systemic Type 2 inflammation, resulting in substantial QoL impairment. In this presentaion, an expert will discuss the effects of an uncontrolled immune response, Type 2 inflammation, on the esophagus and explain the coexisting nature of Type 2 diseases in patients with EoE.
Ardelyx
An Innovative Approach to the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
2:30–3:15 p.m.
DDW Theater 2 - Hall F2
Please join us for an engaging session where Dr. Brooks Cash and Dr. Mark Pimentel will discuss an innovative approach to treat adults with irritable bowel syndrome with constipation (IBS-C).
3:30 p.m.Intercept Pharmaceuticals, Inc.
3:30–4:15 p.m.
DDW Theater 1 - Hall B2
Kris V. Kowdley, MD, will give an informative presentation about taking the treatment of Primary Biliary Cholangitis (PBC) a step further. Learn about an approved treatment for patients with PBC.
Janssen Biotech, Inc.
STELARA®: Data-Driven Outcomes in Ulcerative Colitis (UC) Biologic-naïve Patients* *For adults with moderately to severely active ulcerative colitis
3:30–4:15 p.m.
DDW Theater 2 - Hall F2
Please visit Booth 3526 for Product Theater details.
Speakers: Miguel Regueiro, MD and Anita Afzali, MD, MPH

Sunday, May 23, 2021

9:30 a.m.Castle Biosciences
The Role of TissueCypher in the Management of Barrett’s Esophagus.
9:30–10:15 a.m.
DDW Theater 1 - Hall B2
Learn how a precision medicine test can analyze esophageal biopsies and other clinical risk factors to inform your Barrett’s esophagus patient management. Understand how this prognostic test – supported extensively by published clinical evidence – can assess individual risk of progression to HGD and EAC and easily integrate into your care pathway.
10:30 a.m.GlaxoSmithKline
Exploring Cholestatic Pruritus in PBC — Are We Even Scratching the Surface?
10:30–11:15 a.m.
DDW Theater 2 - Hall F2
Cholestatic pruritus is a serious, chronic condition that adversely impacts the sleep, quality of life, and emotional well-being of people living with PBC. This presentation will discuss how cholestatic itch can be identified and a patient-centric approach to management of cholestatic pruritus.
11:30 a.m.Madrigal Pharmaceuticals
Emerging Concepts in Nonalcoholic Steatohepatitis (NASH)
11:30 a.m.–12:15 p.m.
DDW Theater 1 - Hall B2
This session will explore several emerging NASH concepts, including epidemiology and comorbidities, pathophysiology and the role of lipotoxicity in the liver and patient identification and monitoring approaches.
12:30 p.m.Fractyl Health
The Duodenum: A New Therapeutic Horizon for Metabolic Disease
12:30–1:15 p.m.
DDW Theater 2 - Hall F2
The prevalence and overlap of metabolic diseases including T2D and NAFLD highlights common pathophysiology. Increased dietary sugar and fat consumption contributes to duodenal dysfunction which may potentiate disease progression. This session will discuss the duodenal mucosa as a metabolic regulator and investigational therapy that targets the mucosa for metabolic disease.
1:30 p.m.Eli Lilly
Gut Decision - Bowel Urgency in Ulcerative Colitis
1:30–2:15 p.m.
DDW Theater 1 - Hall B2
Which ulcerative colitis (UC) symptom may impact your patients’ lives the most? Explore this important topic with Dr. Bincy Abraham as she discusses bowel urgency’s true impact on patients through new study data, proposed mechanism of bowel urgency in UC, and a case study.
2:30 p.m.Eli Lilly
Beyond the Gut: The Science of Wellness in Inflammatory Bowel Disease
2:30–3:15 p.m.
DDW Theater 2 - Hall F2
This educational symposium will explore the evidence behind the role of positive interventions that improve resilience in patients with IBD.

Related Opportunities

Satellite Symposia

Industry Supporters can host educational programs before or after DDW scientific sessions, often offering CME to participants.

ICWs are meetings and events arranged by exhibitors, third party planners, educational institutions or other non-profit organizations during DDW.

In-Conjunction With Meetings

ICWs are meetings and events arranged by exhibitors, third-party planners, educational institutions or other non-profit organizations.

Book Your Space

Exceed business goals by exposing your company to key decision makers in GI. The on-site Exhibit Hall will be open May 7-9, 2023.